Bapineuzumab

Bibliography

• Salloway S, Sperling R, Gilman S, A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;10:2061-70
   Google Scholar
• Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006;368:387-403
   PubMed Web of Science ®Google Scholar
• Schenk D, Barbour R, Dunn W, Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-7
   PubMed Web of Science ®Google Scholar
• Janus C, Pearson J, McLaurin J, Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000;408:979-82
   PubMed Web of Science ®Google Scholar
• Morgan D, Diamond DM, Gottschall PE, Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000;408:982-5
   PubMed Web of Science ®Google Scholar
• Bard F, Cannon C, Barbour R, Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916-19
   PubMed Web of Science ®Google Scholar
• DeMattos RB, Bales KR, Cummins DJ, Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:8850-5
   PubMed Web of Science ®Google Scholar
• Asami-Odaka A, Obayashi-Adachi Y, Matsumoto Y, Passive immunization of the Abeta42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease. Neurodegener Dis 2005;2:36-43
   PubMed Web of Science ®Google Scholar
• Gray AJ, Sakaguchi G, Shiratori C, Antibody against C-terminal Abeta selectively elevates plasma Abeta. Neuroreport 2007;18:293-6
   PubMed Web of Science ®Google Scholar
• Kotilinek LA, Bacskai B, Westerman M, Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 2002;22:6331-5
   PubMed Web of Science ®Google Scholar
• Lombardo JA, Stern EA, McLellan ME, Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci 2003;23:10879-83
   PubMed Web of Science ®Google Scholar
• Mohajeri MH, Saini K, Schultz JG, Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation. J Biol Chem 2002;277:33012-17
   PubMed Web of Science ®Google Scholar
• Wilcock DM, Rojiani A, Rosenthal A, Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflamm 2004;1(1):24
   PubMedGoogle Scholar
• Bayer AJ, Bullock R, Jones RW, Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005;64:94-101
   PubMed Web of Science ®Google Scholar
• Gilman S, Koller M, Black RS, Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-62
   PubMed Web of Science ®Google Scholar
• Orgogozo JM, Gilman S, Dartigues JF, Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61:46-54
   PubMed Web of Science ®Google Scholar
• Nicoll JA, Wilkinson D, Holmes C, Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003;9:448-52
   PubMed Web of Science ®Google Scholar
• Ferrer I, Boada Rovira M, Sanchez Guerra ML, Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004;14:11-20
   PubMed Web of Science ®Google Scholar
• Holmes C, Boche D, Wilkinson D, Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372:216-23
   PubMed Web of Science ®Google Scholar
• Masliah E, Hansen L, Adame A, Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005;64:129-31
   PubMed Web of Science ®Google Scholar
• Vellas B, Black R, Thal LJ, Long-term follow-up of patients immunized with AN reduced functional decline in antibody responders. Curr Alzheimer Res 2009;6:144-51
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Knopman DS, Jagust WJ, Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-28
   PubMed Web of Science ®Google Scholar
• Walsh DM, Selkoe DJ. Abeta oligomers: a decade of discovery. J Neurochem 2007;101:1172-84
   PubMed Web of Science ®Google Scholar
• Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 2009;110:1129-34
   PubMed Web of Science ®Google Scholar
• Jicha GA. Is passive immunization for Alzheimer's disease ‘alive and well’ or ‘dead and buried’? Expert Opin Biol Ther 2009;9:481-91
   PubMed Web of Science ®Google Scholar
• Raskind M, Liang E, Sperling R, Pharmacokinetics and pharmacodynamics of bapineuzumab following multiple intravenous infusions in patients with mild-to-moderate Alzheimer's disease. Alzheimers Dement 2009;5:P415-16
   Google Scholar
• Bacher M, Depboylu C, Du Y, Peripheral and central biodistribution of 111In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease. Neurosci Lett 2009;449:240-5
   PubMed Web of Science ®Google Scholar
• Dodart JC, Bales KR, Gannon KS, Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002;5:452-7
   PubMed Web of Science ®Google Scholar
• Yamada K, Yabuki C, Seubert P, Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J Neurosci 2009;29:11393-8
   PubMed Web of Science ®Google Scholar
• Lee M, Bard F, Johnson-Wood K, Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol 2005;58:430-5
   PubMed Web of Science ®Google Scholar
• Lemere CA. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. Prog Brain Res 2009;175:83-93
   PubMed Web of Science ®Google Scholar
• Hansen RA, Gartlehner G, Webb AP, Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging 2008;3:211-25
   PubMed Web of Science ®Google Scholar
• van Marum RJ. Update on the use of memantine in Alzheimer's disease. Neuropsychiatr Dis Treat 2009;5:237-47
   PubMed Web of Science ®Google Scholar
• Shanks M, Kivipelto M, Bullock R, Lane R. Cholinesterase inhibition: is there evidence for disease-modifying effects? Curr Med Res Opin 2009;25:2439-46
   PubMed Web of Science ®Google Scholar
• Munoz-Torrero D. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease. Curr Med Chem 2008;15:2433-55
   PubMed Web of Science ®Google Scholar
• Seubert P, Vigo-Pelfrey C, Esch F, Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992;359:325-7
   PubMed Web of Science ®Google Scholar
• Siemers ER, Friedrich SP, Dean RA, Safety and changes in plasma and cerebrospinal fluid amyloid-beta after a single administration of an amyloid-beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 2010;33:67-73
   PubMed Web of Science ®Google Scholar
• DeMattos RB, Racke MM, Gelfanova V, Identification, characterization, and comparison of amino-terminally truncated Abeta42 peptides in Alzheimer's disease brain tissue and in plasma from Alzheimer's patients receiving solanezumab immunotherapy treatment. Alzheimers Dement 2009;5:P156-7
   Google Scholar
• Seubert P, Barbour R, Khan K, Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. Neurodegener Dis 2008;5(2):65-71
   PubMed Web of Science ®Google Scholar
• Siemers ER, Friedrich S, Dean RA, P4-346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease. Alzheimers Dement 2008;4:T774
   Google Scholar
• Racke MM, Boone LI, Hepburn DL, Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 2005;25:629-36
   PubMed Web of Science ®Google Scholar
• Nicholas T, Knebel W, Gastonguay MR, Preliminary population pharmacokinetic modeling of PF-04360365, a humanized anti-amyloid monoclonal antibody, in patients with mild-to-moderate Alzheimer's disease. Alzheimers Dement 2009;5:P253
   Google Scholar
• Watts RJ, Chen M, Atwal J, Selection of an anti-Abeta antibody that binds various forms of Abeta and blocks toxicity both in vitro and in vivo. Alzheimers Dement 2009;5:P426
   Google Scholar
• Dodel R, Hampel H, Depboylu C, Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol 2002;52:253-6
   PubMed Web of Science ®Google Scholar
• Dodel RC, Du Y, Depboylu C, Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75:1472-4
   PubMed Web of Science ®Google Scholar
• Relkin NR, Szabo P, Adamiak B, 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009;30:1728-36
   PubMed Web of Science ®Google Scholar
• Schneeberger A, Mandler M, Otawa O, Development of AFFITOPE vaccines for Alzheimer's disease (AD) – from concept to clinical testing. J Nutr Health Aging 2009;13:264-7
   PubMed Web of Science ®Google Scholar
• Johnson-Wood K, Lee M, Motter R, Amyloid precursor protein processing and Abeta42 deposition in a transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 1997;94:1550-5
   PubMed Web of Science ®Google Scholar
• Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009;63:287-303
   PubMed Web of Science ®Google Scholar
• Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131-44
   PubMed Web of Science ®Google Scholar
• Fleisher AS, Donohue M, Chen K, Applications of neuroimaging to disease-modification trials in Alzheimer's disease. Behav Neurol 2009;21:129-36
   PubMed Web of Science ®Google Scholar
• Fox NC, Black RS, Gilman S, Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005;64:1563-72
   PubMed Web of Science ®Google Scholar
• Rinne JO, Brooks DJ, Rossor MN, 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363-72
   PubMed Web of Science ®Google Scholar
• Klunk WE, Engler H, Nordberg A, Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19
   PubMed Web of Science ®Google Scholar
• Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neuro 2009;117-28
   PubMed Web of Science ®Google Scholar
• Lopez OL, Hamilton R, Ikonomovic M, In vivo amyloid deposition and neuropathological findings after humanized amyloid beta-specific monoclonal antibodies therapy in a patient with Alzheimer's disease. Alzheimers Dement 2009;5:P64-5
   Google Scholar
• Chalmers K, Wilcock GK, Love S. APOEϵ4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of Abeta protein. Neuropathol Appl Neurobiol 2003;29:231-8
   PubMed Web of Science ®Google Scholar
• Braak H, Alafuzoff I, Arzberger T, Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathologica 2006;112:389-404
   PubMed Web of Science ®Google Scholar
• Scolnik PA. mAbs: a business perspective. MAbs 2009;1:179-84
   PubMed Web of Science ®Google Scholar
• Kim D, Tsai L-H. Bridging physiology and pathology in AD. Cell 2009;137:997-1000
   PubMed Web of Science ®Google Scholar
• Roberson ED, Scearce-Levie K, Palop JJ, Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007;316:750-4
   PubMed Web of Science ®Google Scholar
• Bednar M, Zhao Q, Landen JW, Safety and pharmacokinetics of the anti-amyloid monoclonal antibody PF-04360365 following a single infusion in patients with mild-to-moderate Alzheimer's disease: preliminary results. Alzheimers Dement 2009;5:P157
   PubMedGoogle Scholar
• Mortensen D, Deng R, Adolfsson O, Characterization of the pharmacokinetics, pharmacodynamics, and distribution of anti-abeta antibody MABT5102A. Alzheimers Dement 2009;5:P419
   PubMedGoogle Scholar
• Winblad BG, Minthon L, Floesser A, Results of the first-in-man study with the active Abeta immunotherapy CAD106 in Alzheimer patients. Alzheimers Dement 2009;5:P113-14
   Google Scholar